ME03759B - Inhibitori bromodomena - Google Patents
Inhibitori bromodomenaInfo
- Publication number
- ME03759B ME03759B MEP-2020-128A MEP2020128A ME03759B ME 03759 B ME03759 B ME 03759B ME P2020128 A MEP2020128 A ME P2020128A ME 03759 B ME03759 B ME 03759B
- Authority
- ME
- Montenegro
- Prior art keywords
- bromodomain inhibitors
- bromodomain
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Virology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2016079362 | 2016-04-15 | ||
| EP17781931.5A EP3442972B1 (en) | 2016-04-15 | 2017-04-14 | Bromodomain inhibitors |
| PCT/CN2017/080511 WO2017177955A1 (en) | 2016-04-15 | 2017-04-14 | Bromodomain inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME03759B true ME03759B (me) | 2021-04-20 |
Family
ID=60042835
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2020-128A ME03759B (me) | 2016-04-15 | 2020-12-14 | Inhibitori bromodomena |
Country Status (38)
| Country | Link |
|---|---|
| US (3) | US10633379B2 (me) |
| EP (2) | EP3442972B1 (me) |
| JP (2) | JP6978424B2 (me) |
| KR (1) | KR102250415B1 (me) |
| CN (1) | CN109071534B (me) |
| AR (1) | AR108207A1 (me) |
| AU (2) | AU2017251537B2 (me) |
| BR (1) | BR112018071216A2 (me) |
| CA (1) | CA3018802A1 (me) |
| CL (1) | CL2018002924A1 (me) |
| CO (1) | CO2018011064A2 (me) |
| CR (1) | CR20180541A (me) |
| CY (1) | CY1123025T1 (me) |
| DK (1) | DK3442972T3 (me) |
| DO (1) | DOP2018000227A (me) |
| EC (1) | ECSP18083519A (me) |
| ES (1) | ES2793239T3 (me) |
| HR (1) | HRP20200728T1 (me) |
| HU (1) | HUE050217T2 (me) |
| IL (1) | IL261586B (me) |
| LT (1) | LT3442972T (me) |
| MA (2) | MA44674B1 (me) |
| MD (1) | MD3442972T2 (me) |
| ME (1) | ME03759B (me) |
| MX (1) | MX2018012541A (me) |
| MY (1) | MY190795A (me) |
| PE (1) | PE20190472A1 (me) |
| PH (1) | PH12018501920B1 (me) |
| PL (1) | PL3442972T3 (me) |
| PT (1) | PT3442972T (me) |
| RS (1) | RS60302B1 (me) |
| RU (1) | RU2741808C2 (me) |
| SG (1) | SG11201808003RA (me) |
| SI (1) | SI3442972T1 (me) |
| TW (3) | TWI764237B (me) |
| UA (1) | UA124764C2 (me) |
| UY (1) | UY37205A (me) |
| WO (1) | WO2017177955A1 (me) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA44674B1 (fr) * | 2016-04-15 | 2020-06-30 | Abbvie Inc | Inhibiteurs de bromodomaine |
| AU2016426480A1 (en) * | 2016-10-14 | 2019-04-18 | Abbvie Inc. | Bromodomain inhibitors |
| AU2018254577B2 (en) | 2017-04-21 | 2024-06-13 | Epizyme, Inc. | Combination therapies with EHMT2 inhibitors |
| KR20210038921A (ko) | 2018-07-25 | 2021-04-08 | 치아타이 티안큉 파마수티컬 그룹 주식회사 | 브로모도메인 단백질 억제제로서의 설폭시민 화합물과 약학적 조성물 및 이의 의학적 용도 |
| CN110776508B (zh) * | 2018-07-27 | 2021-07-16 | 海创药业股份有限公司 | 一种brd4抑制剂及其制备方法和用途 |
| CN110964012B (zh) * | 2018-09-29 | 2021-08-13 | 上海凌达生物医药有限公司 | 一类稠杂环联芳基苄醇类化合物、制备方法和用途 |
| AU2019372121A1 (en) | 2018-10-30 | 2021-05-27 | Nuvation Bio Inc. | Heterocyclic compounds as BET inhibitors |
| US20220185808A1 (en) * | 2019-03-17 | 2022-06-16 | Shanghai Ringene Biopharma Co., Ltd. | Acylaminopyrrolo-pyridone compound, preparation method therefor and use thereof |
| GB201905721D0 (en) * | 2019-04-24 | 2019-06-05 | Univ Dundee | Compounds |
| WO2020232214A1 (en) * | 2019-05-14 | 2020-11-19 | Abbvie Inc. | Treating acute myeloid leukemia (aml) with mivebresib, a bromodomain inhibitor |
| BR112021026668A2 (pt) | 2019-07-02 | 2022-02-15 | Nuvation Bio Inc | Compostos heterocíclicos como inibidores de bet |
| KR20220047290A (ko) * | 2019-07-30 | 2022-04-15 | 엑스래드 테라퓨틱스, 인크. | 항종양 요법에 사용하기 위한 이중 atm 및 dna-pk 억제제 |
| CN112625036A (zh) * | 2019-10-08 | 2021-04-09 | 上海海和药物研究开发股份有限公司 | 一类具有brd4抑制活性的化合物、其制备方法及用途 |
| CN115667254A (zh) * | 2020-05-21 | 2023-01-31 | 贝达药业股份有限公司 | 作为溴结构域蛋白质抑制剂的化合物和组合物 |
| GB202016977D0 (en) | 2020-10-26 | 2020-12-09 | In4Derm Ltd | Compounds |
| JP2023538405A (ja) * | 2020-12-01 | 2023-09-07 | 成都苑▲東▼生物制▲薬▼股▲ふん▼有限公司 | 新規ｎ－複素環ｂｅｔブロモドメイン阻害剤、その調製方法及び医薬応用 |
| WO2022228421A1 (zh) * | 2021-04-30 | 2022-11-03 | 成都苑东生物制药股份有限公司 | 一种新型brd4溴结构域protac蛋白降解剂、其制备方法及医药用途 |
| GB2621505B (en) | 2021-06-29 | 2024-07-03 | Tay Therapeutics Ltd | Pyrrolopyridone derivatives useful in the treatment of inflammatory disorders, immune disorders and cancer |
| CN115611890B (zh) * | 2021-07-15 | 2024-05-31 | 成都硕德药业有限公司 | 一种新型噻吩类bet溴结构域抑制剂、其制备方法及医药用途 |
Family Cites Families (174)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO760996L (me) | 1975-03-25 | 1976-09-28 | Byk Gulden Lomberg Chem Fab | |
| US4004012A (en) | 1975-10-14 | 1977-01-18 | Sterling Drug Inc. | 3-Cyano-5-(pyridinyl)-2(1H)-pyridinones |
| US4072746A (en) | 1975-10-14 | 1978-02-07 | Sterling Drug Inc. | 3-Amino-5-(pyridinyl)-2(1H)-pyridinones |
| DE2845456A1 (de) | 1978-10-19 | 1980-08-14 | Merck Patent Gmbh | 6-arylpyridazin-3-one und verfahren zu ihrer herstellung |
| US4298609A (en) | 1979-08-30 | 1981-11-03 | Sterling Drug Inc. | 4,5-Dihydro-6-(4-pyridinyl)-3-pyridazinol and salts, their preparation and use as blood pressure lowering agents |
| FR2478640A1 (fr) | 1980-03-24 | 1981-09-25 | Sanofi Sa | Nouvelles thieno (2,3-d) pyridazinones-4 et thieno (2,3-d) pyridazinones-7, leur procede de preparation et leur therapeutique |
| US4337253A (en) | 1980-04-28 | 1982-06-29 | Sterling Drug Inc. | 4,5-Dihydro-2-methyl-6-(4-pyridinyl)-3(2H)-pyridazinone and its use as a cardiotonic |
| US4305943A (en) | 1980-04-28 | 1981-12-15 | Sterling Drug Inc. | 4-Amino-6-(pyridinyl)-3(2H)-pyridazinones and their use as cardiotonics |
| US4304776A (en) | 1980-04-28 | 1981-12-08 | Sterling Drug Inc. | 4-Substituted-6-(pyridinyl)-3(2h)-pyridazinones and their use as intermediates and cardiotonics |
| US4486431A (en) | 1981-01-14 | 1984-12-04 | Sterling Drug Inc. | Cardiotonic use of 4,5-dihydro-6-(4-pyridinyl)-3(2H)-pyridazinones |
| US4346221A (en) | 1980-04-28 | 1982-08-24 | Sterling Drug Inc. | Preparation of 4-amino-6-(pyridinyl)-3(2H)-pyridazinones from 6-(pyridinyl)-3(2H)-pyridazinones |
| US4338446A (en) | 1980-04-28 | 1982-07-06 | Sterling Drug Inc. | Di-(lower-alkyl)hydroxy-[2-oxo-2-(pyridinyl)ethyl]-propanedioates |
| US4559352A (en) | 1981-03-30 | 1985-12-17 | Sterling Drug Inc. | 1,2-Dihydro-2-oxo-5-(hydroxy-and/or amino-phenyl)-nicotinonitriles and cardiotonic use thereof |
| US4397854A (en) | 1981-05-14 | 1983-08-09 | Warner-Lambert Company | Substituted 6-phenyl-3(2H)-pyridazinones useful as cardiotonic agents |
| US4404203A (en) | 1981-05-14 | 1983-09-13 | Warner-Lambert Company | Substituted 6-phenyl-3(2H)-pyridazinones useful as cardiotonic agents |
| US4515797A (en) | 1981-09-08 | 1985-05-07 | Sterling Drug Inc. | 3-Amino-5-(hydroxy- and/or aminophenyl)-6-(lower-alkyl)-2(1H)-pyridinones and cardiotonic use thereof |
| US4465686A (en) | 1981-09-08 | 1984-08-14 | Sterling Drug Inc. | 5-(Hydroxy- and/or amino-phenyl)-6-(lower-alkyl)-2-(1H)-pyridinones, their cardiotonic use and preparation |
| US4353905A (en) | 1981-09-17 | 1982-10-12 | Warner-Lambert Company | Substituted 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones and 6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones |
| US4599423A (en) | 1982-04-26 | 1986-07-08 | Sterling Drug Inc. | Preparation of 5-(hydroxy- and/or aminophenyl-6-lower-alkyl)-2(1H)-pyridinones |
| US4734415A (en) | 1982-08-13 | 1988-03-29 | Warner-Lambert Company | Substituted 4,5-dihydro-6-(substituted)-phenyl-3(2H)-pyridazinones and 6-(substituted) phenyl-3(2H)-pyridazinones |
| DE3241102A1 (de) | 1982-11-06 | 1984-05-10 | A. Nattermann & Cie GmbH, 5000 Köln | Imidazolylalkylthienyl-tetrahydropyridazine und verfahren zu ihrer herstellung |
| DE3321012A1 (de) | 1983-06-10 | 1984-12-13 | A. Nattermann & Cie GmbH, 5000 Köln | Substituierte 4,5-dihydro-6-(thien-2-yl)-3(2h)-pyridazinone und 6-(thien-2-yl)-3(2h)-pyridazinone sowie verfahren zu ihrer herstellung |
| US4666902A (en) | 1983-06-20 | 1987-05-19 | Cassella Aktiengesellschaft | Tetrahydropyridazinone derivatives, processes for their preparation and their use |
| GB8323553D0 (en) | 1983-09-02 | 1983-10-05 | Smith Kline French Lab | Pharmaceutical compositions |
| US4816454A (en) | 1984-09-21 | 1989-03-28 | Cassella Aktiengesellschaft | 4,5-dihydro-3(2H)-pyridazinones and their pharmacological use |
| US4863745A (en) | 1986-10-22 | 1989-09-05 | Wm. Wrigley Jr. Company | Chewing gum containing zein coated high-potency sweetener and method |
| US5192563A (en) | 1986-10-22 | 1993-03-09 | Wm. Wrigley, Jr. Company | Strongly mint-flavored chewing gums with reduced bitterness and harshness |
| US5221543A (en) | 1986-10-22 | 1993-06-22 | Firma Wilhelm Fette Gmbh | Method of making a fast release stabilized aspartame ingredient for chewing gum |
| US5217735A (en) | 1986-10-22 | 1993-06-08 | Wm. Wrigley Jr. Company | Method of making chewing gum with delayed release ingredients |
| US5112625A (en) | 1989-02-15 | 1992-05-12 | Wm. Wrigley Jr. Company | Aqueous zein coated sweeteners and other ingredients for chewing gum |
| US4908371A (en) | 1987-11-10 | 1990-03-13 | Ciba-Geigy Corporation | Esterified hydroxy dihydropyridinones for treating diseases associated with trivalent metal ion overload |
| US4919941A (en) | 1987-12-18 | 1990-04-24 | Wm. Wrigley Jr. Company | Chewing gum containing delayed release protein sweetener and method |
| DE4134467A1 (de) | 1991-10-18 | 1993-04-22 | Thomae Gmbh Dr K | Heterobiarylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| WO1991012251A1 (en) | 1990-02-19 | 1991-08-22 | Chugai Seiyaku Kabushiki Kaisha | Novel fused heterocyclic compound and antiasthmatic agent prepared therefrom |
| DE4023369A1 (de) | 1990-07-23 | 1992-01-30 | Thomae Gmbh Dr K | Benzimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| ES2131506T3 (es) | 1990-09-21 | 1999-08-01 | Rohm & Haas | Dihidropiridacinonas y piridacinonas como fungicidas. |
| CA2069877A1 (en) | 1990-10-02 | 1992-04-03 | Michio Nakanishi | Ethynylphenyl derivative substituted by pyridazinone and medicament for circulatory disease containing the same as an effective ingredient |
| DE4127404A1 (de) | 1991-08-19 | 1993-02-25 | Thomae Gmbh Dr K | Cyclische iminoderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| CN1038249C (zh) | 1991-08-28 | 1998-05-06 | 罗姆和哈斯公司 | 含有二氢哒嗪酮及其相关化合物的杀菌组合物 |
| US5716954A (en) | 1991-10-09 | 1998-02-10 | Syntex U.S.A. Inc. | Benzopyridazinone and pyridopyridazinone compounds |
| HUT66969A (en) | 1991-10-09 | 1995-01-30 | Syntex Inc | Benzo- and pyrido-pyridazinone- and pyridazin-thion derivatives, pharmaceutical compositions containing the same and process for the production of thereof |
| DE4237656A1 (de) | 1992-06-13 | 1993-12-16 | Merck Patent Gmbh | Benzimidazolderivate |
| EP0666851A4 (en) | 1992-11-02 | 1995-08-30 | Merck & Co. Inc. | Substituted phthalazinones as nerotensin antagonists. |
| US5814651A (en) | 1992-12-02 | 1998-09-29 | Pfizer Inc. | Catechol diethers as selective PDEIV inhibitors |
| EP0634404A1 (en) | 1993-07-13 | 1995-01-18 | Rhone Poulenc Agriculture Ltd. | Phtalazin derivatives and their use as pesticides |
| GB9314412D0 (en) | 1993-07-13 | 1993-08-25 | Rhone Poulenc Agriculture | New compositions of matter |
| TW263498B (me) | 1993-11-10 | 1995-11-21 | Takeda Pharm Industry Co Ltd | |
| JP3247540B2 (ja) | 1994-05-12 | 2002-01-15 | 株式会社日立製作所 | パケット化通信装置および切替え装置 |
| US5466697A (en) | 1994-07-13 | 1995-11-14 | Syntex (U.S.A.) Inc. | 8-phenyl-1,6-naphthyridin-5-ones |
| AU691673B2 (en) | 1994-11-14 | 1998-05-21 | Dow Agrosciences Llc | Pyridazinones and their use as fungicides |
| JPH08337583A (ja) | 1995-04-13 | 1996-12-24 | Takeda Chem Ind Ltd | 複素環化合物およびその製造法 |
| US5635494A (en) | 1995-04-21 | 1997-06-03 | Rohm And Haas Company | Dihydropyridazinones and pyridazinones and their use as fungicides and insecticides |
| JPH11508267A (ja) | 1995-06-26 | 1999-07-21 | 藤沢薬品工業株式会社 | ピラゾール化合物および医薬組成物 |
| IL118631A (en) | 1995-06-27 | 2002-05-23 | Tanabe Seiyaku Co | History of pyridazinone and processes for their preparation |
| AR003978A1 (es) | 1995-08-25 | 1998-09-30 | Rohm & Haas | Composiciones de acidos grasos y piridazinonas que tienen efectos fungitoxicos sinergicos y metodos para controlar hongos. |
| EA001732B1 (ru) | 1996-09-13 | 2001-08-27 | Велфайд Корпорейшн | Тиенотриазолодиазепиновые соединения и лекарственное средство |
| US5855654A (en) | 1997-01-30 | 1999-01-05 | Rohm And Haas Company | Pyridazinones as marine antifouling agents |
| JP2001517228A (ja) | 1997-04-01 | 2001-10-02 | アストラゼネカ・アクチエボラーグ | 新規なピリジン誘導体およびそれを含有する医薬組成物 |
| US6245804B1 (en) | 1997-05-30 | 2001-06-12 | Schering Aktiengesellschaft | Nonsteroidal gestagens |
| US6307047B1 (en) | 1997-08-22 | 2001-10-23 | Abbott Laboratories | Prostaglandin endoperoxide H synthase biosynthesis inhibitors |
| CA2307111C (en) | 1997-11-19 | 2009-06-30 | Kowa Co., Ltd. | Novel pyridazine derivatives and drugs containing the same as the active ingredient |
| CN1284079A (zh) | 1997-12-05 | 2001-02-14 | 阿斯特拉曾尼卡英国有限公司 | 新化合物 |
| EP0934933A1 (en) | 1998-02-06 | 1999-08-11 | Byk Gulden Lomberg Chemische Fabrik GmbH | Phthalazinones |
| TWI241295B (en) | 1998-03-02 | 2005-10-11 | Kowa Co | Pyridazine derivative and medicine containing the same as effect component |
| TW548275B (en) | 1998-07-16 | 2003-08-21 | Shionogi & Co | A pyrimidine derivative having antiturnor activity |
| US6271380B1 (en) | 1998-12-30 | 2001-08-07 | Dupont Pharmaceuticals Company | 1H-imidazo[4,5-d]pyridazin-7-ones, 3H-imidazo-[4,5-c]pyridin-4-ones and corresponding thiones as corticotropin releasing factor (CRF) receptor ligands |
| CN1297916A (zh) | 1999-11-26 | 2001-06-06 | 上海博容基因开发有限公司 | 一种新的多肽——人含溴基结构域的蛋白95和编码这种多肽的多核苷酸 |
| DE10010423A1 (de) | 2000-03-03 | 2001-09-06 | Bayer Ag | Substituierte 2,5-Dimethyldihydropyridazinone und ihre Verwendung |
| CN1315397A (zh) | 2000-03-28 | 2001-10-03 | 上海博德基因开发有限公司 | 一种新的多肽——人溴基结构域10和编码这种多肽的多核苷酸 |
| WO2002001935A1 (en) | 2000-07-04 | 2002-01-10 | Robert John Eyre | Harvesting machine |
| US20030114448A1 (en) | 2001-05-31 | 2003-06-19 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
| JP2003313169A (ja) | 2002-04-19 | 2003-11-06 | Otsuka Chemical Holdings Co Ltd | ４，４−ジフルオロ−３−ブテニル化合物及び農園芸用殺虫・殺ダニ剤 |
| ES2195785B1 (es) | 2002-05-16 | 2005-03-16 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
| AU2003249539A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors |
| WO2004014892A1 (en) | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Monocyclic derivatives as matrix metalloproteinase inhibitors |
| WO2005000818A1 (en) | 2003-06-27 | 2005-01-06 | Warner-Lambert Company Llc | 5-substituted-4-`(substituted phenyl)!amino!-2-pyridone deviatives for use as mek inhibitors |
| US7595316B2 (en) | 2003-06-27 | 2009-09-29 | Banyu Pharmaceutical Co., Ltd. | Heteroaryloxy nitrogenous saturated heterocyclic derivative |
| EP1663211B1 (en) | 2003-08-06 | 2010-01-20 | Vertex Pharmaceuticals Incorporated | Aminotriazole compounds useful as inhibitors of protein kinases |
| AR045595A1 (es) * | 2003-09-04 | 2005-11-02 | Vertex Pharma | Composiciones utiles como inhibidores de proteinas quinasas |
| CA2542047A1 (en) | 2003-10-20 | 2005-05-12 | Merck & Co., Inc. | Hydroxy pyridopyrrolopyrazine dione compounds useful as hiv integrase inhibitors |
| SG115845A1 (en) | 2004-03-31 | 2005-10-28 | Univ Singapore | Modulation of trip-br function and method of treating proliferative disorders |
| BRPI0514925A (pt) * | 2004-09-03 | 2008-07-01 | Yuhan Corp | derivados de pirrol[2,3-c]piridina e processos para a preparação destes |
| GB0420970D0 (en) | 2004-09-21 | 2004-10-20 | Smithkline Beecham Corp | Novel triazoloquinoline compounds |
| WO2006038734A1 (en) | 2004-10-08 | 2006-04-13 | Astellas Pharma Inc. | Pyridazinone derivatives cytokines inhibitors |
| US20080090827A1 (en) | 2004-11-30 | 2008-04-17 | Artesian Therapeutics, Inc. | Compounds With Mixed Pde-Inhibitory and Beta-Adrenergic Antagonist or Partial Agonist Activity For Treatment of Heart Failure |
| US8158652B2 (en) | 2004-12-01 | 2012-04-17 | Msd K.K. | Substituted pyridone derivative |
| CN101208303A (zh) | 2005-03-14 | 2008-06-25 | 默克公司 | Cgrp受体拮抗剂 |
| US20060276496A1 (en) | 2005-03-17 | 2006-12-07 | Boehringer Ingelheim Pharmaceuticals, Inc. | Anti-Cytokine Heterocyclic Compounds |
| JPWO2006112331A1 (ja) | 2005-04-13 | 2008-12-11 | 大日本住友製薬株式会社 | 新規縮合ピロール誘導体 |
| JP5159305B2 (ja) | 2005-05-30 | 2013-03-06 | 田辺三菱製薬株式会社 | チエノトリアゾロジアゼピン化合物及びその医薬としての用途 |
| WO2007008145A1 (en) | 2005-07-08 | 2007-01-18 | Astrazeneca Ab | Heterocyclic sulfonamide derivatives as inhibitors of factor xa |
| WO2007008144A1 (en) | 2005-07-08 | 2007-01-18 | Astrazeneca Ab | Heterocyclic sulfonamide derivatives as inhibitors of factor xa |
| JP5324785B2 (ja) | 2005-10-28 | 2013-10-23 | 武田薬品工業株式会社 | 複素環アミド化合物及びその用途 |
| WO2007070818A1 (en) | 2005-12-14 | 2007-06-21 | Bristol-Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
| US20070142414A1 (en) | 2005-12-16 | 2007-06-21 | Pharmacia Italia S.P.A. | N-substituted pyrrolopyridinones active as kinase inhibitors |
| PL2069312T3 (pl) | 2006-07-25 | 2013-03-29 | Cephalon Inc | Pochodne pirydazynonu |
| WO2008024978A2 (en) | 2006-08-24 | 2008-02-28 | Serenex, Inc. | Tetrahydroindolone and tetrahydroindazolone derivatives |
| US7838523B2 (en) | 2006-09-11 | 2010-11-23 | Cgi Pharmaceuticals, Inc. | Certain substituted amides, method of making, and method of use thereof |
| KR20090087027A (ko) | 2006-11-13 | 2009-08-14 | 일라이 릴리 앤드 캄파니 | 염증 질환 및 암의 치료를 위한 티에노피리미디논 |
| CA2672298C (en) | 2006-12-14 | 2015-02-03 | K.U.Leuven Research & Development | Fused pyridine compounds useful in the prophylaxis or treatment of viral infections |
| JP2008156311A (ja) | 2006-12-26 | 2008-07-10 | Institute Of Physical & Chemical Research | Ｂｒｄ２ブロモドメイン結合剤 |
| US20080312307A1 (en) | 2007-05-25 | 2008-12-18 | Takeda Pharmaceutical Company Limited | Mapk/erk kinase inhibitors |
| JP5451611B2 (ja) | 2007-07-26 | 2014-03-26 | ヴァイティー ファーマシューティカルズ，インコーポレイテッド | １１β−ヒドロキシステロイドデヒドロゲナーゼ１のサイクリックインヒビター |
| CL2008002793A1 (es) | 2007-09-20 | 2009-09-04 | Cgi Pharmaceuticals Inc | Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras |
| ES2499017T3 (es) | 2007-10-23 | 2014-09-26 | F. Hoffmann-La Roche Ag | Nuevos inhibidores de quinasa |
| WO2009054790A1 (en) | 2007-10-26 | 2009-04-30 | Astrazeneca Ab | Amide linked heteroaromatic derivatives as modulators of mglur5 |
| WO2009086303A2 (en) | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| WO2009084693A1 (ja) | 2007-12-28 | 2009-07-09 | Mitsubishi Tanabe Pharma Corporation | 抗癌剤 |
| US20100137320A1 (en) | 2008-02-29 | 2010-06-03 | Schering Corporation | Gamma secretase modulators |
| JP5538365B2 (ja) | 2008-05-01 | 2014-07-02 | ヴァイティー ファーマシューティカルズ，インコーポレイテッド | １１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状阻害剤 |
| US8242111B2 (en) | 2008-05-01 | 2012-08-14 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1 |
| PL2300461T3 (pl) | 2008-05-01 | 2013-09-30 | Vitae Pharmaceuticals Inc | Cykliczne inhibitory dehydrogenazy 11beta-hydroksysteroidów 1 |
| EP2328586A2 (en) | 2008-05-20 | 2011-06-08 | Cephalon, Inc. | Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands |
| EP2687525B1 (en) | 2008-07-25 | 2015-09-23 | Boehringer Ingelheim International GmbH | Cyclic inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 |
| US9284297B2 (en) | 2008-08-11 | 2016-03-15 | President And Fellows Of Harvard College | Halofuginone analogs for inhibition of tRNA synthetases and uses thereof |
| EA019098B1 (ru) | 2008-11-20 | 2014-01-30 | Мерк Шарп Энд Домэ Корп. | Арилметилбензохиназолиноны в качестве позитивных аллостерических модуляторов рецептора м1 |
| EP2196465A1 (en) | 2008-12-15 | 2010-06-16 | Almirall, S.A. | (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors |
| GEP20156309B (en) | 2009-04-30 | 2015-07-10 | Vitae Pharmaceuticals Inc | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| GB0919434D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| EP2955524A3 (en) | 2009-11-05 | 2016-03-23 | GlaxoSmithKline LLC | Novel process |
| KR101424989B1 (ko) | 2009-11-05 | 2014-07-31 | 글락소스미스클라인 엘엘씨 | 벤조디아제핀 브로모도메인 억제제 |
| WO2011054845A1 (en) | 2009-11-05 | 2011-05-12 | Glaxosmithkline Llc | Benzodiazepine bromodomain inhibitor |
| GB0919432D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Use |
| GB0919426D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| GB0919423D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| KR20120095956A (ko) | 2009-11-11 | 2012-08-29 | 이 아이 듀폰 디 네모아 앤드 캄파니 | 2차 루프 냉동 시스템 내의 냉매 저장소 |
| CA2812043A1 (en) | 2010-04-23 | 2011-10-27 | Kineta, Inc. | Pyrimidinedione anti-viral compounds |
| EP2902030B1 (en) | 2010-05-14 | 2016-09-14 | Dana-Farber Cancer Institute, Inc. | Thienotriazolodiazepine compounds for treating neoplasia |
| US20130151333A1 (en) | 2011-12-07 | 2013-06-13 | Affectiva, Inc. | Affect based evaluation of advertisement effectiveness |
| WO2011161031A1 (en) | 2010-06-22 | 2011-12-29 | Glaxosmithkline Llc | Benzotriazolodiazepine compounds inhibitors of bromodomains |
| US9249161B2 (en) | 2010-12-02 | 2016-02-02 | Constellation Pharmaceuticals, Inc. | Bromodomain inhibitors and uses thereof |
| WO2013097052A1 (en) | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Bromodomain inhibitors |
| US20130188311A1 (en) | 2012-01-23 | 2013-07-25 | International Business Machines Corporation | Cooling and noise-reduction apparatus |
| EP2838881B1 (en) | 2012-04-20 | 2018-08-08 | AbbVie Inc. | Isoindolone derivatives |
| KR20150023722A (ko) | 2012-06-12 | 2015-03-05 | 애브비 인코포레이티드 | 피리디논 및 피리다지논 유도체 |
| KR102008733B1 (ko) | 2012-06-15 | 2019-08-09 | 소프트 머신즈, 인크. | 스토어 상위 서열에 기초하여 상이한 스레드들로부터의 포워딩을 구현하는 스레드에 무관한 로드 스토어 버퍼 |
| US20140094456A1 (en) | 2012-10-02 | 2014-04-03 | Intermune, Inc. | Anti-fibrotic pyridinones |
| AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| WO2014125408A2 (en) * | 2013-02-12 | 2014-08-21 | Aurigene Discovery Technologies Limited | Substituted 1h-pyrrolopyridinone derivatives as kinase inhibitors |
| WO2014164771A1 (en) * | 2013-03-11 | 2014-10-09 | Abbvie Inc. | Bromodomain inhibitors |
| EP2970285B1 (en) | 2013-03-11 | 2019-04-17 | AbbVie Inc. | Fused tetracyclic bromodomain inhibitors |
| WO2014165127A1 (en) | 2013-03-12 | 2014-10-09 | Abbvie Inc. | Pyrrole amide inhibitors |
| TW201443051A (zh) * | 2013-03-12 | 2014-11-16 | Abbvie Inc | 二氫－吡咯并吡啶酮抑制劑 |
| CN105026403B (zh) | 2013-03-12 | 2018-05-18 | 艾伯维公司 | 四环布罗莫结构域抑制剂 |
| AR096758A1 (es) | 2013-06-28 | 2016-02-03 | Abbvie Inc | Inhibidores cristalinos de bromodominios |
| SG11201510678TA (en) | 2013-06-28 | 2016-01-28 | Abbvie Inc | Bromodomain inhibitors |
| CN103387576A (zh) * | 2013-08-09 | 2013-11-13 | 中国药科大学 | 基于嘌呤结构的芳酰胺类Raf激酶抑制剂及其制备方法和用途 |
| FI3640241T3 (fi) * | 2013-10-18 | 2023-01-13 | Bromodomeeni-inhibiittorit | |
| US9315501B2 (en) | 2013-11-26 | 2016-04-19 | Incyte Corporation | Bicyclic heterocycles as BET protein inhibitors |
| WO2015081280A1 (en) | 2013-11-26 | 2015-06-04 | Coferon, Inc. | Bromodomain ligands capable of dimerizing in an aqueous solution |
| WO2015081246A1 (en) | 2013-11-26 | 2015-06-04 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
| WO2015081203A1 (en) | 2013-11-26 | 2015-06-04 | Incyte Corporation | Bicyclic heterocycles as bet protein inhibitors |
| JP2016539970A (ja) | 2013-12-09 | 2016-12-22 | アッヴィ・インコーポレイテッド | ブロモドメイン阻害薬として有用なジヒドロピリジノンおよびジヒドロピリダジノン誘導体 |
| AU2014361381A1 (en) | 2013-12-10 | 2016-06-16 | Abbvie Inc. | Bromodomain inhibitors |
| SG11201608843TA (en) | 2014-04-23 | 2016-11-29 | Incyte Corp | 1H-PYRROLO[2,3-c]PYRIDIN-7(6H)-ONES AND PYRAZOLO[3,4-c]PYRIDIN-7(6H)-ONES AS INHIBITORS OF BET PROTEINS |
| MA40940A (fr) | 2014-11-10 | 2017-09-19 | Constellation Pharmaceuticals Inc | Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines |
| WO2016183114A1 (en) | 2015-05-11 | 2016-11-17 | Bristol-Myers Squibb Company | Tricyclic compounds as anticancer agents |
| EP3307740B1 (en) | 2015-05-12 | 2019-12-18 | Bristol-Myers Squibb Company | 5h-pyrido[3,2-b]indole compounds as anticancer agents |
| JP6606444B2 (ja) | 2016-03-10 | 2019-11-13 | 株式会社Ｓｕｂａｒｕ | 車両用制御装置 |
| EP4285996A3 (en) | 2016-04-15 | 2024-01-10 | Blueprint Medicines Corporation | Inhibitors of activin receptor-like kinase |
| BR112018071093A2 (pt) | 2016-04-15 | 2019-01-29 | Epizyme Inc | composto de fórmula, composição farmacêutica, e método para prevenir ou tratar um distúrbio sanguíneo |
| CN109071545B (zh) | 2016-04-15 | 2021-08-03 | 拜耳动物保健有限责任公司 | 新的吡唑并嘧啶衍生物 |
| MA44674B1 (fr) * | 2016-04-15 | 2020-06-30 | Abbvie Inc | Inhibiteurs de bromodomaine |
| KR102445810B1 (ko) | 2016-04-15 | 2022-09-20 | 신젠타 파티서페이션즈 아게 | 제초제 피리다지논 화합물 |
| US11298354B2 (en) | 2016-06-09 | 2022-04-12 | Dana-Farber Cancer Institute, Inc. | Methods of use and pharmaceutical combinations of HDAC inhibitors with BET inhibitors |
| US20190134004A1 (en) | 2016-06-16 | 2019-05-09 | The University Of Chicago | Methods and compositions for treating breast and prostate cancer |
| WO2017223268A1 (en) | 2016-06-22 | 2017-12-28 | Yale University | COMPOSITIONS AND METHODS OF RESENSITIZING CELLS TO BROMODOMAIN AND EXTRATERMINAL DOMAIN PROTEIN INHIBITORS (BETi) |
| CA3039003A1 (en) | 2016-10-14 | 2018-04-19 | Abbvie Inc. | Bromodomain inhibitors |
| AU2016426480A1 (en) | 2016-10-14 | 2019-04-18 | Abbvie Inc. | Bromodomain inhibitors |
| WO2018095933A1 (en) | 2016-11-22 | 2018-05-31 | Université D'aix-Marseille (Amu) | Method of prognosticating, or for determining the efficiency of a compound for treating cancer |
| CN110167939B (zh) | 2017-01-11 | 2021-12-31 | 江苏豪森药业集团有限公司 | 吡咯并[2,3-c]吡啶类衍生物、其制备方法及其在医药上的应用 |
| EP3609896A4 (en) | 2017-04-14 | 2020-11-04 | AbbVie Inc. | BROMODOMAIN INHIBITORS |
| CN108976278B (zh) | 2017-06-05 | 2021-04-06 | 海创药业股份有限公司 | 一种嵌合分子及其制备和应用 |
| CN108690020A (zh) | 2018-07-04 | 2018-10-23 | 清华大学 | 一种靶向降解bet蛋白的化合物及其应用 |
-
2017
- 2017-04-14 MA MA44674A patent/MA44674B1/fr unknown
- 2017-04-14 UA UAA201811188A patent/UA124764C2/uk unknown
- 2017-04-14 CR CR20180541A patent/CR20180541A/es unknown
- 2017-04-14 CN CN201780023689.1A patent/CN109071534B/zh active Active
- 2017-04-14 TW TW109127958A patent/TWI764237B/zh active
- 2017-04-14 PE PE2018001988A patent/PE20190472A1/es unknown
- 2017-04-14 SI SI201730258T patent/SI3442972T1/sl unknown
- 2017-04-14 RU RU2018140061A patent/RU2741808C2/ru active
- 2017-04-14 RS RS20200588A patent/RS60302B1/sr unknown
- 2017-04-14 AU AU2017251537A patent/AU2017251537B2/en active Active
- 2017-04-14 PL PL17781931T patent/PL3442972T3/pl unknown
- 2017-04-14 KR KR1020187030341A patent/KR102250415B1/ko active IP Right Grant
- 2017-04-14 MA MA052814A patent/MA52814A/fr unknown
- 2017-04-14 MX MX2018012541A patent/MX2018012541A/es unknown
- 2017-04-14 HU HUE17781931A patent/HUE050217T2/hu unknown
- 2017-04-14 MY MYPI2018703563A patent/MY190795A/en unknown
- 2017-04-14 SG SG11201808003RA patent/SG11201808003RA/en unknown
- 2017-04-14 TW TW111113671A patent/TW202304907A/zh unknown
- 2017-04-14 US US16/093,483 patent/US10633379B2/en active Active
- 2017-04-14 DK DK17781931.5T patent/DK3442972T3/da active
- 2017-04-14 EP EP17781931.5A patent/EP3442972B1/en active Active
- 2017-04-14 TW TW106112643A patent/TWI704147B/zh active
- 2017-04-14 MD MDE20190228T patent/MD3442972T2/ro unknown
- 2017-04-14 EP EP20160781.9A patent/EP3693369A3/en not_active Withdrawn
- 2017-04-14 ES ES17781931T patent/ES2793239T3/es active Active
- 2017-04-14 WO PCT/CN2017/080511 patent/WO2017177955A1/en active Application Filing
- 2017-04-14 JP JP2018545668A patent/JP6978424B2/ja active Active
- 2017-04-14 PT PT177819315T patent/PT3442972T/pt unknown
- 2017-04-14 CA CA3018802A patent/CA3018802A1/en active Pending
- 2017-04-14 LT LTEP17781931.5T patent/LT3442972T/lt unknown
- 2017-04-14 BR BR112018071216A patent/BR112018071216A2/pt active Search and Examination
- 2017-04-17 AR ARP170100968A patent/AR108207A1/es not_active Application Discontinuation
- 2017-04-18 UY UY0001037205A patent/UY37205A/es not_active Application Discontinuation
-
2018
- 2018-09-04 IL IL261586A patent/IL261586B/en active IP Right Grant
- 2018-09-07 PH PH12018501920A patent/PH12018501920B1/en unknown
- 2018-10-12 DO DO2018000227A patent/DOP2018000227A/es unknown
- 2018-10-12 CL CL2018002924A patent/CL2018002924A1/es unknown
- 2018-10-16 CO CONC2018/0011064A patent/CO2018011064A2/es unknown
- 2018-11-08 EC ECSENADI201883519A patent/ECSP18083519A/es unknown
-
2020
- 2020-04-27 US US16/858,930 patent/US20200255426A1/en not_active Abandoned
- 2020-05-06 HR HRP20200728TT patent/HRP20200728T1/hr unknown
- 2020-05-22 CY CY20201100494T patent/CY1123025T1/el unknown
- 2020-12-14 ME MEP-2020-128A patent/ME03759B/me unknown
-
2021
- 2021-01-08 AU AU2021200101A patent/AU2021200101A1/en not_active Abandoned
- 2021-02-24 US US17/183,832 patent/US20220017511A1/en not_active Abandoned
- 2021-11-10 JP JP2021183089A patent/JP2022024026A/ja not_active Ceased
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME03759B (me) | Inhibitori bromodomena | |
| HK1243326A1 (zh) | 溴結構域抑制劑 | |
| HK1245248B (zh) | 被取代的雜環作為溴結構域抑制劑 | |
| HK1243072A1 (zh) | 布羅莫結構域抑制劑及其用途 | |
| HK1243415A1 (zh) | 溴結構域抑制劑 | |
| SG11201802665VA (en) | Ferroportin inhibitors | |
| ZA201903100B (en) | Magl inhibitors | |
| IL266550A (en) | Magl inhibitors | |
| GB201615282D0 (en) | Tankyrase inhibitors | |
| ZA201903099B (en) | Magl inhibitors | |
| HK1243948A1 (zh) | 溴結構域抑制劑 | |
| IL265139B (en) | Dopamine-b-hydroxylase inhibitors | |
| ZA201907136B (en) | Ip6k inhibitors | |
| HK1250926A1 (zh) | 抑制劑及其應用 | |
| GB201612860D0 (en) | Inhibitors | |
| GB201501004D0 (en) | Inhibitors | |
| EP3526210A4 (en) | BROMODOMAIN INHIBITORS | |
| EP3528810A4 (en) | BROMODOMAIN INHIBITOR | |
| IL274550A (en) | Dopamine-B-hydroxylase inhibitors | |
| EP3526197A4 (en) | BROMDOMAIN INHIBITORS | |
| GB201520949D0 (en) | Inhibitors | |
| ZA201807614B (en) | Bromodomain inhibitors | |
| GB201721465D0 (en) | Inhibitors | |
| GB201720189D0 (en) | Dopamine-B-hydroxylase inhibitors | |
| GB201519382D0 (en) | Kinase inhibitors |